Surgical primary treatment of stage IVA cervical cancer: A multicenter retrospective study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15551-e15551
Author(s):  
Patrizio Damiani ◽  
Francesco Plotti ◽  
Marzio Angelo Zullo ◽  
Carlo De Cicco Nardone ◽  
Roberto Montera ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Retrospective Study ◽  
Pelvic Exenteration ◽  
Frozen Section ◽  
Colorectal Anastomosis ◽  
Disease Free Survival ◽  
Primary Treatment ◽  
Total Pelvic Exenteration ◽  
Systematic Lymphadenectomy ◽  
Paraaortic Lymph Nodes

e15551 Background: The aim of the present study is to describe feasibility, surgical technique, perioperative data, early and late complications of anterior and total pelvic exenteration after neoadjuvant chemotherapy as primary treatment for stage IVa cervical cancer. Methods: It is a retrospective study which included 73 consecutive patients affected by stage IVa cervical cancer who required anterior or total pelvic exenteration referred to 3 international gynaecologic oncology centres. The steps of this extirpative surgical procedure were: 1) staging laparotomy; 2) frozen section biopsy of the paraaortic lymph nodes; 3) systematic lymphadenectomy, radical hysterectomy with adnexectomy and total or anterior pelvic exenteration; 4) continent urinary diversions and low colorectal anastomosis if it was possible. Results: The treatment of patients affected by FIGO stage IVA cervical cancer remains one of the most complex procedures gynecologic oncologists are faced with. Our study focused on clinical and operative data , in terms of overall survival (OS) and disease free survival (DFS) at 5 years. 5-year OS of our series was 43%. Conclusions: The surgical treatment of stage IVA cervical cancer appears therefore a suitable and valid alternative. Stage IVA cervical cancer patients in good general condition, with a disease resectable with clear surgical margins, should be considered for primary exenteration in referral centers where the surgical experience to perform this procedure is available.

Surgical primary treatment of stage IVA cervical cancer: A multicentre retrospective study

2012 ◽  
Vol 125 ◽  
pp. S52
Author(s):  
R. Angioli ◽  
A. Soderini ◽  
F. Plotti ◽  
P. Damiani ◽  
R. Montera ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Retrospective Study ◽  
Primary Treatment ◽  
Multicentre Retrospective Study

Total Pelvic Exenteration/Radical Hysterectomy for Cervical Cancer

1996 ◽  
pp. 29-30
Author(s):  
Ralph H. Hruban ◽  
William H. Westra ◽  
Timothy H. Phelps ◽  
Christina Isacson
Keyword(s):  
Cervical Cancer ◽  
Radical Hysterectomy ◽  
Pelvic Exenteration ◽  
Total Pelvic Exenteration

A retrospective study about the oncological outcome of pelvic exenteration in recurrent/residual cervical cancer

2021 ◽  
Vol 47 (2) ◽  
pp. e28-e29
Author(s):  
Dharma Poonia ◽  
Gs Bhati ◽  
Tara ram Choudhary ◽  
Amit Sehrawat ◽  
Pankaj Kumar Garg ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Retrospective Study ◽  
Pelvic Exenteration ◽  
Oncological Outcome

Concomitant weekly carboplatin (CB) and paclitaxel (P) with pelvic radiotherapy (RT) for the treatment of advanced cervical cancer (ACC): A FNCLCC gynecologic group phase I trial

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5542-5542 ◽  
Author(s):  
C. Lhomme ◽  
T. Petit ◽  
R. Largillier ◽  
F. Mayer ◽  
A. Floquet ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Complete Response ◽  
Figo Stage ◽  
Primary Treatment ◽  
External Irradiation ◽  
Hematologic Toxicity ◽  
Ct Dose ◽  
Phase Ii Studies ◽  
Paraaortic Lymph Nodes

5542 Background: Standard primary treatment for locally ACC is RT with concomitant chemotherapy (CT). CB and P are radiosensitizers with in vitro synergistic action. Methods: Patients (pts) with FIGO stage IIB-IVA negative paraaortic lymph nodes cervical cancer were treated with 6 weekly cycles of CT during pelvic RT (45 Gy) and brachytherapy (BT) according to Table 1 . Each dose escalation step followed a 30-day period of observation on cohorts of 3 to 6 pts depending on dose limiting toxicity (DLT): toxic death; garde (G) 4 neutropenia > 1 week; G 4 toxicity (other hematologic or non-hematologic); any toxicity requiring = 1 week delay in RT, or > 2 dose reductions of CT, or G 3/4 hematologic toxicity > 3 weeks after treatment’s end; unendurable G 3 non hematologic toxicity. Results: 23 pts were included by 5 centers in 5 dose levels (L). Stage distribution: IIB (10), III (11), IVA (2); 20 epidermoid and 3 adenocarcinoma; ECOG: 0 (16), 1 (7). 22 pts received the 6 planned cycles. Median dose of irradiation was 45 Gy (43.2–50) with no toxicity related interruption. 17 pts underwent BT, 2 had hysterectomy and 1 received complementary external irradiation 12 Gy. CT dose reduction was necessary in 4 pts (cycle 5 or 6) and cycles postponed for 10 pts (cycle. 5 or 6). One pt experienced paclitaxel allergy at L1. G 3 anemia and/or neutropenia were reported in 11 pts and G 4 neutropenia = 1 week in 2 pts. Radiodermatitis occurred in 5 pts, asthenia in 3 and nausea in 1. One DLT was observed: unendurable G 3 asthenia + G 3 neutropenia and leucopenia at L3. Clinical and radiological complete response was obtained in 13 pts, 5 PRs and 2 SDs in 20 evaluable pts. Conclusions: Acceptable toxicity and optimal irradiation were possible at L4 in 7 pts. These doses are recommended for future phase II studies of concomitant CT/RT in ACC. [Table: see text] No significant financial relationships to disclose.

Post neoadjuvant chemo-radiation positive anterior circumferential resection margin in carcinoma rectum: Extended resection of rectum versus total pelvic exenteration—Results from a single centre retrospective study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15156-e15156
Author(s):  
Kamlesh Verma ◽  
Reena Engineer ◽  
Vikas S. Ostwal ◽  
Suman Kumar ◽  
Supreeta Arya ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Hospital Stay ◽  
Circumferential Resection Margin ◽  
Resection Margin ◽  
Pelvic Exenteration ◽  
Total Pelvic Exenteration ◽  
Duration Of Hospital Stay ◽  
Significant Difference ◽  
Carcinoma Rectum

e15156 Background: Positive circumferential resection margin has been shown to be powerful predictor of poor prognosis in rectal CA. Radiologically positive anterior CRM (PACRM) after NACT+RT leads to either resection of involved organ alone ie.Extended resection of rectum (ERR) or Total pelvic exenteration (TPE). Purpose of this study is to compare recurrence rate and survival of patients undergoing ERR or TPE for PACRM after NACT+RT. Methods: Retrospective study of patients operated for rectal CA from January 2013 to December 2014. Results: Out of 237 patients with non-metastatic CA rectum, 51 patients (21.5%) had PACRM. After NACT+RT, 22 patients (43.1%) developed systemic metastases, 7 patients (13.8%) were downsized and underwent extra-mesorectal resection (AR/APR), remaining 22 patients (43.1%) had persistent PACRM. 13 patients with PACRM underwent ERR whereas 9 patients underwent TPE. Median duration of hospital stay in TPE group was 13 days (10 - 26) whereas it was 7 days (5 – 21) in ERR group. Negative pathological CRM was achieved in all TPE and 92.3% of ERR patients. After median follow-up of 31.6 months, 5 patients with TPE (55.6%) and 4 patients with ERR (30.7%) developed systemic recurrence. None of the TPE patient, whereas 3 patients with ERR (23.1%) developed local recurrence. Median D.F.S. was 12.3 months in TPE and 18.9 months in ERR whereas mean O.S. was 36.2 and 32.8 respectively. Conclusions: Due to lack of significant difference in O.S./ D.F.S. and low post-operative complication and duration of hospital stay, ERR can be considered acceptable alternative to TPE.

Laparoscopic sphincter preserving total pelvic exenteration for recurrent cervical cancer ‐ a video vignette

2021 ◽  
Author(s):  
Haiyang Zhou ◽  
Ping Wu ◽  
Yi Wu ◽  
Yu Shi ◽  
Chao Liu ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Pelvic Exenteration ◽  
Total Pelvic Exenteration ◽  
Recurrent Cervical Cancer ◽  
Video Vignette

Resection of recurrent cervical cancer after total pelvic exenteration

2007 ◽  
Vol 17 (1) ◽  
pp. 137-140 ◽  
Author(s):  
S. M. Mourton ◽  
Y. Sonoda ◽  
N. R. Abu-Rustum ◽  
B. H. Bochner ◽  
R. R. Barakat ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Median Time ◽  
Pelvic Exenteration ◽  
Femoral Nerve ◽  
Psoas Muscle ◽  
Total Pelvic Exenteration ◽  
Recurrent Cervical Cancer ◽  
Time To Recurrence ◽  
Initial Recurrence ◽  
Alive With Disease

The objective of this study was to describe the management of patients with recurrent cervical cancer after total pelvic exenteration (TPE). We reviewed the records of patients who underwent TPE for recurrent cervical cancer between June 1992 and December 2003 and subsequently developed recurrent disease. Thirty-seven patients underwent TPE during the study period, and 25 (68%) subsequently developed recurrence proven by radiographic and/or biopsy studies. Recurrence sites included pelvic (12), inguinal (5), retroperitoneal (5), hepatic (4), vulva (2), perineum (1), transposed ovary (1), and lung (1). The median time to recurrence was 7 months (range 2–73 months), with 92% (23/25) occurring within 2 years of TPE. Management of recurrence was known in 21 of 25 patients, which included chemotherapy (10), surgical resection (7), and no further treatment (4). Surgically resected recurrences were isolated to the groin (2), vulva (2), perineum (1), transposed ovary (1), and psoas muscle (1). The four patients who underwent ovarian, perineal, and vulvar resections succumbed to their disease in a median time of 13 months (range 2–21 months). Of the two patients with surgically resected groin recurrences, one is alive with disease 21 months after initial recurrence and the other is alive without evidence of disease 85 months later. One patient had an isolated 4-cm recurrence involving the psoas muscle and the femoral nerve and is without the evidence of disease 9 months later. Resection of isolated recurrences after TPE is a reasonable option in selected patients, particularly in those with solitary inguinal metastases

scholarly journals Use of bakri balloon catheter and pedicled omental flap in combination for pelvic reconstruction after total pelvic exenteration

2021 ◽  
Author(s):  
samin almassian
Keyword(s):  
Cervical Cancer ◽  
Pelvic Exenteration ◽  
Balloon Catheter ◽  
Omental Flap ◽  
Advanced Cervical Cancer ◽  
Pelvic Reconstruction ◽  
Total Pelvic Exenteration ◽  
Aged Woman ◽  
Middle Aged Woman ◽  
Bakri Balloon

Our case was a middle-aged woman with advanced cervical cancer that underwent pelvic exenteration (PE) and then pelvic reconstruction (PR) with omental flap and bakri balloon placement.

Sign in / Sign up

Export Citation Format

Share Document